{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-026890","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.866966+00:00","generated_at":"2026-06-21T22:20:37.461555+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dyadic Q3 net loss $1.8M; SAHPRA clears Phase 1 COVID-19 vaccine trial","bullets":["Net loss $1.809M ($0.06/share); revenue $0.88M vs $0.693M YoY increase.","Cash and investments $14.2M; expects to fund operations into 2024.","SAHPRA approved Phase 1 trial for DYAI-100 COVID-19 RBD booster; enrollment planned later 2022.","R&D expenses fell to $0.744M from $1.902M YoY as pre-clinical activities wound down.","9x improvement in Nivolumab expression to 22.3 g/L; livestock antigen titers up to 10 g/L."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-026890","json":"https://secwatch.observer/filing/0001437749-22-026890.json","markdown":"https://secwatch.observer/filing/0001437749-22-026890.md","text":"https://secwatch.observer/filing/0001437749-22-026890.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000143774922026890/0001437749-22-026890-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000143774922026890/dyai20220814_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:20:37.461555+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"85eccd44968a7b32ede7fe01959fd1336671a22d","claim":"DYADIC INTERNATIONAL INC reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 10, 2022, Dyadic International, Inc. (\"Dyadic”) issued a press release announcing its results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213809/000143774922026890/0001437749-22-026890-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}